Related Experiment Video

Updated: Jul 27, 2025

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.4K

Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges

Carlo Sorrentino1,2, Emma Di Carlo1,2

  • 1Department of Medicine and Sciences of Aging, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.

Cancers
|June 10, 2023
PubMed

Insights

Novel targeted therapies show promise for metastatic prostate cancer, particularly prostate-specific membrane antigen-targeted radionuclide therapies and DNA repair inhibitors. Further research is needed for other approaches like anti-angiogenesis and immune checkpoint inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Prostate cancer is a leading malignancy in men, with poor prognosis for metastatic disease despite advances in localized treatment.
  • Metastatic castration-resistant prostate cancer (mCRPC) presents significant therapeutic challenges.

Purpose of the Study:

  • To review novel molecular targeted therapies for mCRPC.
  • To discuss the efficacy and challenges of emerging prostate cancer treatments.
  • To highlight future research directions in prostate cancer therapy.

Main Methods:

  • Comprehensive review of relevant studies and clinical trials on targeted therapies for prostate cancer.
  • Analysis of therapeutic approaches including radionuclide therapies, DNA repair inhibitors, anti-angiogenesis, and immune checkpoint inhibitors.

Main Results:

  • Prostate-specific membrane antigen-targeted radionuclide therapies and DNA repair inhibitors show significant promise in mCRPC, with some FDA-approved protocols.
  • Therapies targeting tumor neovascularization and immune checkpoint inhibitors have not yet shown clear clinical benefits in mCRPC.

Conclusions:

  • Targeted therapies represent a promising frontier for treating metastatic prostate cancer, especially mCRPC.
  • Continued research and clinical trials are essential to overcome challenges and improve outcomes for advanced prostate cancer patients.
Keywords:
anti-angiogenic therapycastration-resistant prostate cancerimmunotherapymetastasismolecular targeted therapies

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
73